Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by fox7mfon Mar 12, 2023 8:54am
224 Views
Post# 35333218

RE:RE:Cancer will cost the world $25 trillion over next 30 years

RE:RE:Cancer will cost the world $25 trillion over next 30 yearsInteresting. All BP currently involved in negotiations with Onc must be on cloud 9 thinking of all the revenue Pela could bring in. BP must be even more excited knowing that, in this current market, Oncy's once strong positioning at the negotiation table due to strong science is evaporating along with its SP. Make no mistake, SP matters. Hostile takeovers could happen. $10b buyouts won't happen. Even if the SP doesn't further decline, and it likely will, BP would never be able to sell a multi billion dollar acquisition to shareholders if the acquisition in question has a $1usd SP. How will Onc remedy this ? Noteable suggests BP will pursue AA after they acquire Onc...so how does the BOD get the market cap up to $1-$2b before B/O? I need an answer to this question. 
<< Previous
Bullboard Posts
Next >>